Ticker Launch
Sign inGet notified

SPAC · Deal announced · BKHA

Black Hawk Acquisition Corp

Business combination with Vesicor Therapeutics, Inc.

Black Hawk Acquisition Corp (BKHA) is a blank-check company (SPAC) that raised $69M in its initial public offering on Mar 22, 2024, listing on Nasdaq Global Market. It agreed to combine with Vesicor Therapeutics, Inc., announced on Apr 29, 2025, at a stated value of $70M. The deal has not closed yet. EF Hutton led the IPO. Ogier advised the SPAC and Robinson & Cole advised the underwriters on the IPO.

Vesicor Therapeutics, Inc. is a California-based, early development stage biotechnology company developing p53-based cancer therapeutics delivered through precision-engineered microvesicles. It signed a business combination agreement with Black Hawk Acquisition in April 2025.

Status
Deal announced
Ticker
BKHA
IPO date
Mar 22, 2024
IPO size
$69M
IPO exchange
Nasdaq Global Market
Target
Vesicor Therapeutics, Inc.
Target sector
Biotech
Announced
Apr 29, 2025
Stated deal value
$70M
Combined company
Vesicor Therapeutics Holdings, Inc.
IPO underwriters
EF Hutton
SPAC counsel (IPO)
Ogier
Underwriters' counsel (IPO)
Robinson & Cole

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Get notified at launchOpen in Ticker Launch

Then $99/month or $999/year. Cancel anytime.

Filings

Other pending SPAC mergers